Also see: Electronic Arts: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES

Abbott Labs ( ABT) price target cut at Barclays to $55 from $60 on fears of weak Humira sales, Barclays said. Maintain Overweight rating.

Airgas ( ARG) estimates, target upped at Jefferies. ARG estimates were boosted through 2012, Jefferies said. Company can deliver above-average growth and generates healthy free cash flow. Buy rating and new $70 price target.

Bank of America ( BAC) estimates cut at Oppenheimer through 2012. Company is seeing weaker trading results and higher costs. Perform rating.

BB&T ( BBT) estimates, target raised at Jefferies. Shares of BBT now seen reaching $31, according to Jefferies. Estimates also increased, given improving credit trends. Hold rating.

Cisco Systems ( CSCO) price target higher at Barclays to $24 from $22 on steady markets and stabilizing outlook, Barclays said. Maintain Equal Weight rating.

Eaton ( ETN) estimates, target boosted at UBS. Shares of ETN now seen reaching $106. Estimates also upped, to match the company's new guidance. Neutral rating.

First Solar ( FSLR) added to Conviction Buy List at Goldman. $165 price target. Company is the low-cost provider and earnings visibility is improving.

General Electric ( GE) price target raised at Credit Suisse to $23 from $22 on improving Power data points, Credit Suisse said. Maintain Outperform rating.

General Electric ( GE) numbers upped at Morgan Stanley through 2012, Morgan Stanley said. Company is carrying a lot of momentum into the new year. Overweight rating and new $23 price target.

Hewlett-Packard ( HPQ) numbers raised at Brean Murray. Shares of HPQ now seen reaching $60. Estimates also increased, given higher sales growth potential. Buy rating.

Intuitive Surgical ( ISRG) numbers boosted at Goldman. Shares of ISRG now seen reaching $270, according to Goldman Sachs. Estimates also upped, given higher sales and a lower share count. Sell rating.

MetLife ( MET) estimates, target raised at Citigroup. Shares of MET now seen reaching $54, according to Citigroup. Estimates also increased, given a higher expected ROE. Buy rating.

Merck & Co ( MRK) price target lowered at Barclays to $41 from $43. Products coming out in 2011 and 2012 appear small in revenue upside, Barclays said. Maintain Overweight rating.

Navigators ( NAVG) estimates lowered at Credit Suisse. NAVG 2010 and 2011 EPS estimates reduced to $2.52 and $3.50, respectively. Reducing estimates for reinstatement premiums, Credit Suisse said. Maintain Neutral rating and $49 price target.

Netgear ( NTGR) price target boosted at Barclays to $39 from $36. Expecting strong 4Q10 results due to healthy WiFi trends and solid holiday retail environment, Barclays said. Maintain Overweight rating.

PNC Financial ( PNC) numbers increased at Citigroup. PNC estimates were raised through 2012, Citigroup said. Company has a strong capital position and credit trends are improving. Hold rating and new $70 price target.

Phillips-Van Heusen ( PVH) numbers lowered at Citigroup. Shares of PVH now seen reaching $82, according to Citigroup. Estimates also cut, given gross margin pressures. Buy rating.

Schlumberger ( SLB) estimates, target boosted at Citigroup. Shares of SLB now seen reaching $110, Citigroup said. Estimates also upped, as the company is seeing better North American results. Buy rating.

Suntrust ( STI) estimates, target increased at Jefferies. STI estimates were raised through 2013, Jefferies said. Company is seeing better credit and sales trends. Hold rating and new $32 price target.

Safeway ( SWY) estimates, target reduced at Citigroup. Shares of SWY now seen reaching $18, according to Citigroup. Estimates also cut, given continued price competition. Sell rating.

AT&T ( T) estimates lowered at Morgan Stanley. T estimates were reduced through 2012, Morgan Stanley said. Company is facing increased wireless competition from VZ. Overweight rating and $32 price target.

Watson Pharmaceuticals ( WPI) numbers upped at Goldman. WPI estimates were boosted through 2013, Goldman Sachs said. Company has solid earnings visibility. Neutral rating and new $55 price target.

Watson Pharmaceuticals ( WPI) price target raised at Credit Suisse to $64 from $60. Positive commentary at investor meeting and increased guidance, Credit Suisse said. Maintain Outperform rating.
This article was written by a staff member of TheStreet.